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ABSTRACT  
Two methods for the simultaneous estimation of atorvastatin calcium, glimepiride and metformin hydrochloride in three-component solid 
dosage forms have been developed. First method involved solving simultaneous equations based on measurement of absorbance at three 
wavelengths, 247.2 nm, 224.8 nm and 236 nm as the λmax of atorvastatin calcium, glimepiride and metformin hydrochloride respectively while 
in the second method the instrument is preprogrammed to collect and compile the spectral data from the scan of standards and produces the 
result by matrix calculations. The linearity for three drugs was in the range of 5-30 μg/ml. The procedures were successfully applied for the 
simultaneous determination of three drugs in laboratory prepared mixtures and commercial tablet preparation. High recovery and low % COV 
revealed the reliability of the methods indicating proposed methods are accurate and precise for the simultaneous estimation of three drugs in 
pure and tablet formulation. 
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1. INTRODUCTION 
Chemically, atorvastatin calcium is [R-(R*,R*)-2-(4-
fluorophenyl)-β -dihydroxy-5-(1-methylethyl)-3-phenyl-4-
[(phenylamino)carbonyl]-1H-pyrrole-1-heptonic acid-
calcium salt (2:1) trihydrate used as a synthetic cholesterol-
lowering agent. Glimepiride is a sulphonylurea antidiabetic 
drug and is chemically 3-ethyl-2,5-dihydro-4-methyl-N-[2-
[4-[[[(trans-ethyl 
cyclohexyl)amino]carbonyl]amino]sulphonyl]ethyl]2-oxo-
1H-pyrrole-1-carboxamide Metformin hydrochloride is an 
oral antidiabetic drug and is chemically N, N-dimethyl 
imidodicarbonimidic diamide  Analytical methods, such as 
RP- HPLC [1], and HPTLC [2] have been reported for the 
estimation of atorvastatin calcium from its formulations. 
UHPLC-MS/MS method for determination of atorvastatin 
calcium in human plasma is also reported [3]. A literature 
study found that HPLC [4], LC-MS/MS [5] techniques are 
recorded for the assessment of glimepiride. RP HPLC [6] and 
stability indicating HPTLC [7] method for estimation of 
glimepiride and metformin hydrochloride is reported. UV 
Spectrophotometric [8] method for estimation of metformin 
alone is reported. Simultaneous estimation of metformin, 
glimepiride and atorvastatin in combined tablet dosage form 
by UPLC [9] and Stability Indicating RP-HPLC are also 
reported [10]. A combination of atorvastatin calcium, 
glimepiride, and metformin hydrochloride is commercially 
available in a tablet dosage form. Literature shows that there 
is no technique of analyzing these three drugs in 
combination at the same time by spectrophotometry. So we 
communicate here rapid and cost-effective quality-control 
tool for routine quantitative analysis of all three drugs in 
their combined dosage forms by spectrophotometry. 
2. EXPERIMENTAL 
2.1. Materials 
UV-visible double beam spectrophotometer, Shimadzu 
model 1700 with 1 nm spectral bandwidth, ± 0.3 nm 
wavelength precision and a couple of 10 mm matching 
quartz cells were used. The commercially available tablet, 
cdpro 2 (Label claim: atorvastatin calcium 10 mg, 
glimepiride 2 mg and metformin hydrochloride 500 mg) was 
procured from the local market.   
2.2. Selection of common solvent 
Methanol was selected as a common solvent for developing 
spectral characteristics of the drug. The selection was made 
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after assessing the solubility of three drugs in different 
solvents. 
2.3. Preparation of standard stock and calibration curve  
The standard stock solutions of atorvastatin calcium, 
glimepiride, and metformin hydrochloride were prepared by 
dissolving 10 mg of each drug in 10mL of methanol in 10 mL 
of the volumetric flask to get a solution containing 1000 
µg/mL of each drug. From the above solution, 0.1 ml solution 
was taken and diluted to 10 ml with methanol to get a 
solution containing 10 µg/ mL. 
Working standard solutions of 10 µg/mL were scanned in 
the entire UV range of 400-200 nm to determine the λmax of 
these drugs. The λmax of atorvastatin calcium, glimepiride, 
and metformin hydrochloride was found to be 247.2 nm, 
224.8 nm, and 236 nm respectively (Figure-1). Six working 
standard solutions for three drugs having concentration 5, 
10, 15, 20, 25, 30 µg/mL was prepared in methanol from the 
stock solution. The absorbance of resulting solutions for 
three drugs were measured at their respective λmax and a 
calibration curve was plotted against concentration to get 
the linearity and regression equation of three drugs.
  
 
Figure 1. Overlain spectra of atorvastatin calcium, glimepiride and metformin hydrochloride 
 
2.4 Method I: Simultaneous equation method 
Simultaneous equation method of analysis was based on the 
absorption of drugs (atorvastatin calcium, glimepiride, and 
metformin hydrochloride) at the wavelength maximum of 
each other. Three wavelengths selected for the development 
of the simultaneous equations were 247.2 nm, 224.8 nm, and 
236 nm λ max of atorvastatin calcium, glimepiride, and 
metformin hydrochloride respectively. The absorbance of 
three drugs was measured at 247.2 nm, 224.8 nm, and 236 
nm. The absorptivity values determined at 247.2 nm, 224.8 
nm and 236 nm for atorvastatin were 0.0457 (ax1), 0.0342 
(ax2), 0.0418 (ax3); for glimepiride 0.0142 (ay1), 0.0633 
(ay2), 0.0409 (ay3); for metformin hydrochloride 0.0438 
(az1), 0.0621 (az2), 0.0931 (az3). These values are means of 
six estimations. Thus absorptivity coefficients were 
substituted in the following equations to obtain the 
concentration of three drugs.     
MHGlAC xCxCxCA 0438.00142.00457.01  ….........Eqn.1 
MHGlAC xCxCxCA 0621.00633.00342.02  ……...Eqn. 2 
MHGlAC xCxCxCA 0931.00409.00418.03  ………..Eqn.3 
Where CAC, CGl, and CMH are concentration the of atorvastatin, 
glimepiride and metformin hydrochloride respectively. A1, 
A2, and A3 are the absorbance of the mixture at 247.2 nm, 
224.8 nm, and 236 nm respectively and concentration of 
three drugs in the sample were determined using Eqn.1, 2 
and 3. 
2.6. Method II: Multiwavelength Spectroscopy 
In this method, the instrument is preprogrammed to collect 
and compile the spectral data from the scan of standards and 
produces the result by matrix calculations. Five mixed 
standards of atorvastatin calcium, glimepiride and 
metformin hydrochloride having concentrations in µg/mL 
0.1:0.02:5, 0.2:0.04:10, 0.3:0.06:15, 0.4:0.08:20 and 
0.5:0.1:25 were prepared in methanol by diluting 
appropriate volumes of standard stock solutions and 
scanned between 400 nm to200 nm. Sampling wavelengths 
(247.2 nm, 224.8 nm, 236 nm, and 240nm) were selected on 
the trial and error basis. The concentration of individual 
drugs was feed to the multi-component mode of the 
instrument. The instrument collects and compiles the 
spectral data from mixed standards and the concentration of 
each component was obtained by spectral data of sample 
solution regarding that of five mixed standards. As outlined 
in Method I, a tablet sample solution was prepared. The 
spectrophotometric analysis of the resulting solution was 
carried out using the multicomponent mode of the 
instrument.
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Table1. Analysis data of tablet formulation 
Method Drug 
Label 
claim 
mg/tab 
Amount 
found* 
mg/tab 
Label 
claim 
(%) 
S.D.* % COV S.E*. 
I 
AC 10 9.980 99.80 0.9894 0.9913 0.4039 
Gl 2 2.0034 100.17 0.3771 0.3764 0.1539 
MH 500 500.65 100.13 0.7527 0.7517 0.3072 
 
II 
AC 10 9.985 99.85 0.5471 0.5479 0.2233 
Gl 2 2.011 100.56 0.6521 06484 0.2662 
MH 500 502.1 100.43 0.4781 0.4760 0.1951 
AC: Atorvastatin Calcium, Gl: Glimepiride, MH: Metformin hydrochloride, S.D.: Standard deviation, COV: Coefficient of variation, 
S.E.: Standard error, *Average of six estimation of tablet formulation 
 
Figure 2. Overlain Spectra of Mixed Standard of Atorvastatin Calcium, Glimepiride and Metformin Hydrochloride 
 
2.5. Analysis of the tablet formulations   
Twenty tablets of marketed formulation were accurately 
weighed and powdered. A standard addition method has 
been used for drug assessment. A quantity of powder 
equivalent to 5 mg of metformin hydrochloride was weighed 
and dissolved in 10mL of methanol Then the solution was 
filtered through Whatman filter paper no 41. From the above 
solution, 0.2 mL of solution was taken and diluted to 10 mL 
with the same solvent to get a solution containing 10 µg/mL 
of metformin hydrochloride and the corresponding 
concentration of atorvastatin calcium and glimepiride. To 
this, 0.05mL of stock solution (1000 µg/mL) of pure 
atorvastatin calcium and glimepiride was added and volume 
was made up to the mark with methanol. The purpose of this 
addition was to bring the concentration of atorvastatin 
calcium and glimepiride in the linearity range. With this 
addition, the concentration of atorvastatin calcium, 
glimepiride and metformin hydrochloride in the samples 
was brought to 5.2, 5.04 and 10 µg/mL respectively. Analysis 
operation with tablet formulation was repeated six times. 
The result of the analysis of tablet formulation was reported 
in Table 1. 
2.7. Validation11 
2.7.1 Accuracy 
The accuracy of the established technique was verified by 
conducting 80%, 100%, 120% replicate analysis (n= 3) 
retrieval research following ICH standards at three distinct 
concentration concentrations. Standard medication 
solutions were introduced here to a pre-analyzed sample 
solution and then the proportion of drug content was 
calculated. Table 2 disclosed the results of precision 
research. From the recovery study, it was clear that the 
method is very accurate for quantitative estimation of 
atorvastatin calcium, glimepiride and metformin 
hydrochloride in a tablet dosage form as the statistical 
results were within the acceptance range (S.D. < 2.0). 
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Table 2. Result of recovery studies 
Tablet Brand Method 
Recovery 
level 
(Added 
amount) 
Percent recovery+ SD# 
AC Gl MH 
cdpro 2 (Label claim: atorvastatin 
calcium 10 mg, glimepiride 2 mg 
and metformin hydrochloride 
500 mg) 
 
I 
80% 100.20 +0.342 100.45+0.457 99.50+0.453 
100% 99.50+ 0.571 100.1+0.742 100.54+0.462 
120% 98.50+0.457 100.84+0.561 99.47+0.471 
 
II 
80% 98.56+0.354 98.40+0.483 101.45+0.542 
100% 100.40+0.451 98.50+0.561 100.20+0.562 
120% 98.50+0.587 101.60+0.874 99.30+0.541 
          AC: Atorvastatin Calcium, Gl: Glimepiride, MH: Metformin hydrochloride, S.D.: Standard deviation, 
          # Average of three estimation at each level of recovery 
2.7.2. Precision 
By studying repeatability and intermediate precision, 
precision was determined. 
2.7.2.1. Repeatability 
The result of repeatability indicates the accuracy over a 
short time and inter-assay precision under the same 
operating conditions. The standard deviation, coefficient of 
variance and standard error were calculated for three drugs. 
Repeatability with tablet formulation was conducted six 
times. The statistical assessment findings are presented in 
Table 1. 
2.7.2.2. Intermediate Precision (Inter-day and Intra-day 
precision) 
Intermediate precision was carried out by doing intra and 
inter-day precision study. In intraday study concentration of 
three drugs was calculated on the same day at an interval of 
one hour. In the inter-day study, the concentration of drug 
content was calculated on three different days. Study 
expresses within laboratory variation on different days. In 
both intra- and inter-day precision study for methods 
percentage of COV was not more than 1.0 % indicates good 
intermediate accuracy (Table 3). 
 
Table 3. Optical characteristics data and validation parameters 
Parameters Values 
 AC Gl MH 
Maximum absorbance (λ max) 247.2nm 224.8nm 236nm 
Beer’s law limit (µg/ml) 5-30 5-30 5-30 
Absorptivity* 0.0457 0.0633 0.0931 
Correlation coefficient* 0.997 0.983 0.986 
Intercept* 0.048 0.106 0.059 
Slope* 0.042 0.056 0.088 
LOD* (µg/ml) 0.1278 0.4532 0.0241 
LOQ*(µg/ml) 1.6587 0.7354 0.5781 
Intra-Day* (Precision) (% COV) 0.4581 0.3562 0.7845 
Inter-Day (Precision)  (% COV) n=3 0.8650 0.5874 0.6521 
AC: Atorvastatin Calcium, Gl: Glimepiride, MH: Metformin hydrochloride, S.D.: Standard   deviation, COV: Coefficient of 
variation, * Average of six determination. 
 
2.7.3. Linearity 
Appropriate dilutions of standard stock solutions have been 
tested according to the techniques established for each drug. 
The Beer- Lambert’s concentration range was found to be 5-
30 µg/mL for atorvastatin calcium, glimepiride, and 
metformin hydrochloride. The linearity data for both 
methods are presented in Table 3. 
 
2.7.4. Limit of Detection (LOD) and Limit of Quantitation 
(LOQ)  
The LOD & LOQ of atorvastatin calcium, glimepiride, and 
metformin hydrochloride by proposed methods were 
determined using calibration standards. LOD and LOQ were 
calculated as 3.3/S and 10/S respectively, where S is the 
slope of the calibration curve and  is the standard deviation 
of response.  
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3. RESULTS AND DISCUSSION 
The Beer- Lambert’s concentration range was found to be 5-
30 µg/mL for atorvastatin calcium, glimepiride, and 
metformin hydrochloride at 247.2 nm, 224.8 nm and 236 nm 
wavelengths and coefficient of correlation were found 0.997, 
0.983 and 0.986 respectively. All three drugs showed good 
regression values at their respective wavelengths and the 
results of the recovery study revealed that any small change 
in the drug concentration in the solution could be accurately 
determined by the proposed methods. 
Percentage estimation of three drugs found in tablet dosage 
form were 99.80, 100.17 and 100.13 as per method I while 
99.85, 100.56, 100.43 as per method II for atorvastatin 
calcium, glimepiride, and metformin hydrochloride 
respectively with standard deviation <2 (Table 1). 
In method II five mixed standard and three sampling 
wavelengths were selected through rational 
experimentation keeping in view the number of drugs in the 
formulation and molar absorptivity coefficients of all three 
drugs (Fig. 2). The method requires no manual calculations, 
produces comparable results to the first method and is more 
suitable as compared to the method I. 
The validity and reliability of the proposed methods were 
assessed by recovery studies. Sample recoveries for both the 
methods are in good agreement with their respective label 
claims, which suggested non-interference of formulation 
additives in estimation (Table-2). 
Precision was determined by studying the repeatability and 
intermediate precision. Repeatability result indicates the 
precision under the same operating conditions over a short 
interval time and inter-assay precision. The standard 
deviation, coefficient of variance and standard error were 
calculated for atorvastatin calcium, glimepiride, and 
metformin hydrochloride (Table 1). The intermediate 
precision study expresses within laboratory variation on 
different days. In both intra and inter-day precision studies 
for both the methods %COV were not more than 1.0 % 
indicates good intermediate precision (Table 3). 
The LOD values were 0.1278, 0.4532 and 0.0241 µg/mL and 
LOQ values were 1.6587, 0.7354 and 0.5781 µg/mL for 
atorvastatin calcium, glimepiride and metformin 
hydrochloride respectively. Low values of LOD and LOQ 
indicated good sensitivity of proposed methods. 
4. CONCLUSION 
The results of the analysis of two drugs from tablet 
formulation using all the three developed methods were 
found close to 100% for atorvastatin calcium, glimepiride, 
and metformin hydrochloride, the standard deviation was 
satisfactorily low indicating accuracy and reproducibility of 
the methods. Recovery trials have been satisfactory, showing 
that excipients are not interfering. The developed methods 
were found to be simple, rapid, and accurate and can be used 
for routine estimation of three drugs from tablet 
formulations. 
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